Skip to content

Dr. Chiaravallotti Adele

Ophthalmologist, Researcher
FondazioneBietti_Chiaravallotti Adele
Research line: Research Line of Medical and surgical retina
Research unit: RU Medical Retina
Simple Operating Unit: Simple Operating Unit Medical Retina, low vision and visual rehabilitation 
Specialization: Ophthalmologist, Researcher
Professional register: Provincial Register of Physicians and Surgeons of Crotone (Order of the Province of Crotone), No. 1033 dated 15.05.2001

Practices at IRCCS Fondazione G.B. Bietti across the sites of Via Livenza, 3 and Via di Santo Stefano Rotondo, 6, within the Presidio Ospedaliero Britannico, Rome.

Scientific publications: PubMed

 

  • October 26, 1999 – Degree in Medicine and Surgery from the University of Rome “La Sapienza” with final grade 110/110 cum laude.

  • May 2000 – License to practice as a Physician and Surgeon from the University of Rome “La Sapienza”.

  • October 30, 2003 – Specialization in Ophthalmology from the University of Rome “La Sapienza” with final grade 70/70 cum laude.

  • Since 2001 – Registered with the Medical Association of Rome.

  • January 2018 – present – Medical Director with a permanent contract at IRCCS Fondazione G.B. Bietti for Research in Ophthalmology, with clinical activity at the Maculopathy Center of the “Complesso Ospedaliero San Giovanni-Addolorata.”

  • 2016 – 2017 – Coordinated and continuous collaboration contract at IRCCS Fondazione G.B. Bietti for Research in Ophthalmology, with clinical activity at the Maculopathy Center of the “Complesso Ospedaliero San Giovanni-Addolorata.”

  • 2015 – present – Project-based contract at IRCCS Fondazione G.B. Bietti for Research in Ophthalmology.

  • June 1, 2008 – December 31, 2014 –

    • Project-based contract at IRCCS Fondazione G.B. Bietti for Research in Ophthalmology.

    • Coordinated and continuous collaboration contract at the Maculopathy Center of the “Complesso Ospedaliero San Giovanni-Addolorata.”

  • January 2006 – December 2007 – Research fellowship in the field of medical retina, funded by IRCCS Fondazione G.B. Bietti for Research in Ophthalmology (Medical Retina Department, directed by Dr. M. Varano). Activities included diagnostics through fluorescein angiography, indocyanine green angiography, microperimetry with SLO and MP1, and therapy of chorioretinal and macular diseases with laser, photodynamic therapy, and intravitreal injections of anti-VEGF drugs.

  • January 2004 – December 2005 – Research fellowship in the field of vitreoretinal diseases, funded by IRCCS Fondazione G.B. Bietti for Research in Ophthalmology, involving both clinical-surgical and research activities.

  • AIMO

  • Functional and morphological retinal changes in diabetic macular edema treated with Pegaptanib.

  • Open-label, 12-month study to evaluate the safety and efficacy of intravitreal ranibizumab administered in combination with Visudyne® photodynamic therapy (PDT) in naïve patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration.

  • Six-month, phase 3, multicenter, double-masked, randomized, placebo-controlled study (with a 6-month open-label extension) to evaluate the safety and efficacy of sustained-release 700 μg and 350 μg dexamethasone (DEX PS DDS) in patients with macular edema following central or branch retinal vein occlusion.

  • MONTBLANC Study. A 12-month randomized, double-masked, multicenter, phase II trial assessing safety and efficacy of verteporfin (Visudyne®) photodynamic therapy administered in conjunction with Lucentis™ versus Lucentis™ monotherapy in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration.

  • VIEW2 Study. Randomized, double-masked, active-controlled, phase 3 study of the efficacy, safety, and tolerability of repeated intravitreal VEGF Trap-Eye in patients with neovascular age-related macular degeneration (AMD).

  • DEGAS Study. Phase II prospective, randomized, multicenter, dose-ranging comparator study evaluating the efficacy and safety of PF-04523655 versus laser therapy in diabetic macular edema.

  • GALILEO Study. Randomized, double-masked, sham-controlled, phase 3 study of the efficacy, safety, and tolerability of repeated intravitreal VEGF Trap-Eye in patients with macular edema secondary to central retinal vein occlusion (CRVO).

  • MIZAR Study. Clinical safety and efficacy comparison of NEVANAC® 0.1% to vehicle following cataract surgery in patients with diabetic retinopathy.

  • Phase III, 12-month, randomized, double-masked, multicenter, active-controlled study to evaluate the efficacy and safety of two dosing regimens of 0.5 mg ranibizumab versus verteporfin PDT in patients with visual impairment due to choroidal neovascularization secondary to pathologic myopia.

  • RETAIN Study. Two-year, randomized, single-masked, multicenter, controlled phase IIIb trial assessing the efficacy and safety of 0.5 mg ranibizumab in two “treat and extend” regimens versus 0.5 mg ranibizumab as needed in patients with diabetic macular edema.

  • COMO Study. 12-month, multicenter, randomized, parallel-group study comparing the efficacy and safety of Ozurdex® versus Lucentis® in patients with branch retinal vein occlusion.

  • VIVID DME Study. Randomized, double-masked, active-controlled, phase III study on the efficacy and safety of repeated intravitreal VEGF Trap-Eye injections in patients with diabetic macular edema.

  • Multicenter, open-label, randomized study comparing the efficacy and safety of 700 μg DEX PS DDS versus ranibizumab in patients with diabetic macular edema.

  • Phase 3, randomized, double-masked, controlled trial assessing the safety and efficacy of intravitreal administration of Fovista (Anti PDGF-B pegylated aptamer) combined with Lucentis versus Lucentis monotherapy in patients with subfoveal neovascular AMD (Fovista-OPH1002).

  • MINERVA Study. 12-month, randomized, double-masked, sham-controlled, multicenter trial evaluating the efficacy and safety of 0.5 mg intravitreal ranibizumab in patients with VEGF-driven choroidal neovascularization.

  • AZURE Study. Open-label, randomized, active-controlled, parallel-group phase 3b trial of the efficacy, safety, and tolerability of 2 mg aflibercept intravitreal injections administered under two different regimens in patients with neovascular AMD.

  • ARIES Study. Two-year, randomized, open-label, active-controlled, parallel-group phase IV/IIIb trial evaluating 2 mg intravitreal aflibercept under a Treat and Extend regimen for neovascular AMD.

  • CENTERA Study. Multicenter, single-arm, interventional phase IV trial assessing Treat and Extend regimen of aflibercept in macular edema secondary to central retinal vein occlusion.

  • Safety and efficacy of Abicipar Pegol in patients with neovascular AMD.

  • Fovista-OPH1004 Study. Phase 3 trial on intravitreal Fovista® (E10030) in combination with Avastin® or Eylea® versus Avastin® or Eylea® monotherapy in neovascular AMD.

  • SEQUOIA Study. Safety and efficacy of Abicipar Pegol (AGN-150998) in patients with neovascular AMD.

  • IMAGINE Study. One-year, single-arm, open-label, multicenter phase IV trial using multimodal imaging to guide disease activity through predictive biomarkers of fluid resolution in wAMD patients treated with brolucizumab.

  • COMINO Study. Phase III, multicenter, randomized, double-masked, active comparator-controlled trial evaluating faricimab in macular edema secondary to central or hemiretinal vein occlusion.

  • COAST Study. Phase III, multicenter, randomized, double-masked trial of intravitreal OPT-302 in combination with aflibercept versus aflibercept monotherapy in neovascular AMD.

  • PULSAR Study. Randomized, double-masked, active-controlled, phase 3 trial evaluating high-dose aflibercept in patients with neovascular AMD.

  • CHRONIC CENTRAL SEROUS CHORIORETINOPATHY: Early and Late Morphological and Functional Changes After Verteporfin Photodynamic Therapy. Iacono P, Tedeschi M, Boccassini B, Chiaravalloti A, Varano M, Parravano M. Retina. 2018 Jan 16. doi: 10.1097/IAE.0000000000002040. [Epub ahead of print] 
  • FACTORS INFLUENCING VISUAL ACUITY IN PATIENTS RECEIVING ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR FOR MYOPIC CHOROIDAL NEOVASCULARIZATION. Iacono P, Battaglia Parodi M, Selvi F, Parravano MC, Chiaravalloti A, Varano M, Bandello F. Retina. 2017 Oct;37(10):1931-1941. doi: 10.1097/IAE.0000000000001436. 
  • Exploring the morphological and functional retinal changes after dexamethasone intravitreal implant (Ozurdex®) in macular edema due to retinal vein occlusion. Parravano M, Oddone F, Boccassini B, Giorno P, Chiaravalloti A, Tedeschi M, Scarinci F, Varano M. Ophthalmic Res. 2014;51(3):153-60. doi: 10.1159/000357275. Epub 2014 Mar 13. 
  • Photodynamic therapy in subfoveal and juxtafoveal myopic choroidal neovascularization: a 10-year retrospective analysis. Varano M, Iacono P, Giorno P, Chiaravalloti A, Parravano M.
    Ophthalmologica. 2014;231(4):204-10. doi: 10.1159/000357504. Epub 2014 Jan 25. 
  • Single-session photodynamic therapy combined with intravitreal ranibizumab for neovascular age-related macular degeneration: a comprehensive functional retinal assessment.
    Parravano M, Parisi V, Ziccardi L, Chiaravalloti A, Tedeschi M, Cacciamani A, Boccassini B, Boninfante A, Varano M.
    Doc Ophthalmol. 2013 Dec;127(3):217-25. doi: 10.1007/s10633-013-9404-z. Epub 2013 Aug 13. 
  • Functional and structural assessment of lamellar macular holes. Parravano M, Oddone F, Boccassini B, Chiaravalloti A, Scarinci F, Sciamanna M, Boninfante A, Tedeschi M, Varano M.
    Br J Ophthalmol. 2013 Mar;97(3):291-6. doi: 10.1136/bjophthalmol-2011-301219. Epub 2012 Dec 19. 
  • Foveal microstructure and functional parameters in lamellar macular hole. Reibaldi M, Parravano M, Varano M, Longo A, Avitabile T, Uva MG, Zagari M, Toro M, Boscia F, Boccassini B, Chiaravalloti A, Mariotti C, Reibaldi A. Am J Ophthalmol. 2012 Dec;154(6):974-980.e1. doi: 10.1016/j.ajo.2012.06.008. Epub 2012 Sep 8. 
  • Reproducibility of macular thickness measurements using Cirrus SD-OCT in neovascular age-related macular degeneration. Parravano M, Oddone F, Boccassini B, Menchini F, Chiaravalloti A, Schiavone M, Varano M. Invest Ophthalmol Vis Sci. 2010 Sep;51(9):4788-91. doi: 10.1167/iovs.09-4976. Epub 2010 Apr 30. 
  • Retinal functional changes measured by microperimetry in neovascular age-related macular degeneration treated with ranibizumab: 24-month results. Parravano M, Oddone F, Tedeschi M, Chiaravalloti A, Perillo L, Boccassini B, Varano M. Retina. 2010 Jul-Aug;30(7):1017-24. doi: 10.1097/IAE.0b013e3181cfd3c6. 
  • Choroidal neovascularization in angioid streaks and pseudoxanthoma elasticum: 1 year follow-up. Schiano Lomoriello D, Parravano MC, Chiaravalloti A, Varano M. Eur J Ophthalmol. 2009 Jan-Feb;19(1):151-3. 
  • Retinal functional changes measured by microperimetry in neovascular age-related macular degeneration patients treated with ranibizumab. Parravano M, Oddone F, Tedeschi M, Schiano Lomoriello D, Chiaravalloti A, Ripandelli G, Varano M. Retina. 2009 Mar;29(3):329-34. doi: 10.1097/IAE.0b013e31819093e6. 
  • Posterior vitreous detachment and retinal detachment after cataract surgery. Ripandelli G, Coppé AM, Parisi V, Olzi D, Scassa C, Chiaravalloti A, Stirpe M. Ophthalmology. 2007 Apr;114(4):692-7. Epub 2007 Jan 17. 
Skip to content